Findings

What do systematic reviews say?

32 questions · 32 findings · 4 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 11 · 34.4%GRADE not reported 9 · 28.1%Very low 6 · 18.8%Low 2 · 6.3%Moderate 4 · 12.5%High 0 · 0%

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

Complications of surgery · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

Change in QoL SNOT‐20 · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

FEV1 % predicted: absolute change from baseline · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

Eradication of bacterial infection · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

Clinical improvement(visual analogue scale) · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

Pulmonary exacerbations · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Summary of findings for nasal irrigation with topical steroids plus sinus surgery vs nasal irrigation with topical steroids alone

All‐cause mortality · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis

The review found no eligible studies for this question.

1 finding from 1 review

Surgery for nasal polyposis in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Preoperative blood transfusion vs no transfusion

Perioperative complications ‐ any surgery‐related · people with SCD

Preoperative blood transfusion showed no clear difference in perioperative complications ‐ any surgery‐related compared with no transfusion (low certainty).

1 finding from 1 review

Preoperative blood transfusions for sickle cell disease 2020 · Cochrane Headline outcomes only
RR 0.24 [0.03, 2.05]
1 study · 65 participants
Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Number of minor postoperative bleeding episodes · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
This outcome was not reported in either of the trials.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Outcome not reported · People with Von Willebrand disease undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
No randomised or quasi-randomised controlled trials in people with Von Willebrand disease met the inclusion criteria; no eligible VWD trials were identified.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Major bleeding, requiring transfusion of packed red blood cells · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Only reported in the Walsh (EACA) trial: in none of the 31 included participants was blood transfusion required.
1 study · 31 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Change in haemoglobin level from baseline · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Mean fall in haemoglobin. Forbes (TXA): 1.4 g/100 mL (placebo) vs 0.3 g/100 mL (TXA). Walsh (EACA): 6.3% (placebo, both centres) vs 3.9% and 3.7% (EACA, centres 1 and 2); differences not significant. Reported in…
2 studies · 59 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Bleeding duration · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
This outcome was not reported in either of the trials.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Need for and dose of clotting factor concentrates · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Reported in both trials in different ways. Forbes (TXA): mean units of replacement therapy per root extracted 617 IU (range 0 to 15,800) in 11 placebo participants versus 30 IU and 65 IU per root in 2 TXA participants…
2 studies · 59 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Any postoperative complication except bleeding (e.g. wound infection) · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
This outcome was not reported in either of the trials.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Number of postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… probably leads to lower number of postoperative bleeding episodes requiring intervention compared with placebo, no intervention or usual care (with or without placebo) (moderate certainty).

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Up to 10 days postoperative
RD -0.57 [-0.76, -0.37]
2 studies · 59 participants
Moderate

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Amount of postoperative blood loss (mL) · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Only reported in the Forbes (TXA) trial: over five-day follow-up, mean blood loss per participant 84.1 mL (range 4 to 323) in the placebo group (n=14) versus 61.2 mL (range 1 to 749) in the TXA group (n=14), P = 0.02.
1 study · 28 participants
GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Immediate (<24 h) and delayed (24 h to 10 days)
This outcome was not reported in either of the trials.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Side effects or other adverse events · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Up to 10 days postoperative
RD 0.034 [-0.32, 0.38]
2 studies · 59 participants
Low

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs standard local care

Major bleeding, requiring transfusion of packed red blood cells · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in major bleeding requiring transfusion of packed red blood cells compared with standard care (usual local haemostatic measures: gelatin sponge and…; GRADE not reported.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes
7 days
RD 0.00 [-0.04, 0.04]
2 studies · 125 participants
GRADE not reported